|
gptkbp:instanceOf
|
opioid
|
|
gptkbp:administeredBy
|
gptkb:tablet
injection
oral solution
|
|
gptkbp:ATCCode
|
N02AX06
|
|
gptkbp:bioavailability
|
90% (oral)
|
|
gptkbp:CASNumber
|
27216-93-5
|
|
gptkbp:chemicalFormula
|
C16H23NO2
|
|
gptkbp:combines
|
gptkb:naloxone
|
|
gptkbp:compatibleWith
|
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:controlled_substance
|
yes
|
|
gptkbp:developedBy
|
gptkb:Knoll_AG
|
|
gptkbp:discoveredBy
|
1970
|
|
gptkbp:drugClass
|
opioid
|
|
gptkbp:eliminationHalfLife
|
3-5 hours
|
|
gptkbp:excretion
|
renal
biliary
|
|
gptkbp:has_risk_of_dependence
|
yes
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Tilidine
|
|
gptkbp:IUPACName
|
(E)-ethyl 1-(2-(dimethylamino)cyclohexyl)-2-phenyl-1-pentenoate
|
|
gptkbp:legal_status_in_Germany
|
prescription only
|
|
gptkbp:legal_status_in_Switzerland
|
prescription only
|
|
gptkbp:legal_status_in_United_States
|
not approved
|
|
gptkbp:marketedAs
|
gptkb:Tilidin
gptkb:Valoron
|
|
gptkbp:mechanismOfAction
|
mu-opioid receptor agonist
|
|
gptkbp:metabolism
|
nortilidine
bisnortilidine
|
|
gptkbp:molecularWeight
|
261.36 g/mol
|
|
gptkbp:pregnancyCategory
|
C (Germany)
|
|
gptkbp:proteinBinding
|
20%
|
|
gptkbp:PubChem_CID
|
5487
5285
CHEMBL2104667
|
|
gptkbp:routeOfAdministration
|
oral
parenteral
|
|
gptkbp:sideEffect
|
nausea
constipation
dizziness
sweating
respiratory depression
euphoria
|
|
gptkbp:synonym
|
tilidate
tilidinum
|
|
gptkbp:UNII
|
6X9OC3H4II
|
|
gptkbp:used_in
|
gptkb:Germany
gptkb:Switzerland
|
|
gptkbp:usedFor
|
pain management
|
|
gptkbp:bfsParent
|
gptkb:Tilidin
gptkb:Schedule_I_(UN_Single_Convention_on_Narcotic_Drugs)
|
|
gptkbp:bfsLayer
|
8
|